Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
University of California, San Francisco
BioXcel Therapeutics Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
University of California, San Francisco
University of California, San Francisco
Eli Lilly and Company
Vincerx Pharma, Inc.
Advaxis, Inc.
University of Wisconsin, Madison
Xencor, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gary Onik MD